Search

everythinglearnresearchcommunity

for

Search:↓

The review highlights the importance of stem cells in hair health and suggests new treatment strategies for hair loss conditions.

Dermoscopy shows that diffuse alopecia areata progresses through specific hair growth stages.

Telogen Effluvium is a common hair loss condition, particularly in women, with no specific FDA-approved treatment, and recovery can take up to 18 months.

Washing test helps identify hair loss type, low iron levels significant.

Most HIV patients in the study showed skin and mucous membrane issues, with oral thrush being the most common.

Telogen Effluvium is a common hair loss condition that can be short-term or long-lasting and is often caused by stress, illness, or nutritional issues.

The document explains the causes, types, diagnosis, and treatments of hair loss, and its psychological impact, especially on women.

Hair loss from telogen effluvium may not happen again after another surgery.

Hair ages and thins due to factors like inflammation and stress, and treatments like antioxidants and hormones might improve hair health.

A woman experienced temporary hair loss after jaw surgery due to the stress of the operation.

Acute telogen effluvium can be resolved by addressing causes, but chronic telogen effluvium is harder to treat.

Older adults in Vietnam often experience hair loss after COVID-19, especially women, singles, and those hospitalized.

Hair loss from Telogen Effluvium can be managed by treating the underlying cause and may improve with treatments like minoxidil.

Telogen Effluvium is a common, usually reversible hair loss condition, often improved by removing the trigger and possibly treated with various products, though their effectiveness is uncertain.

Hair loss can be treated with medications like minoxidil and finasteride or surgery, but treatment effectiveness varies by alopecia type and accurate diagnosis is important.

COVID-19 can cause hair loss starting as early as 18 days after infection.

Many people experienced hair loss after having COVID-19, with the worst cases in hospitalized patients, and some saw hair regrowth within six months.

The document concludes that Telogen Effluvium is a hair loss disorder that can be assessed with the modified wash test and may be treated with clobetasol foam, with patient management being important.

Higher levels of ischemia-modified albumin in telogen effluvium patients may indicate oxidative stress.

Some medications, including retinoids, antifungals, and psychotropic drugs, can cause reversible hair loss if stopped or doses are reduced.

Women's hair loss can be due to hormonal changes and various conditions, with treatments focusing on stopping progression and managing symptoms.

Telogen effluvium is a condition that causes temporary hair loss.

New treatments for hair loss should target eight main causes and use specific plant compounds and peptides for better results.

The conclusion is that treatments for Telogen Effluvium exist, but standard treatment guidelines are needed.

COVID-19 patients often experience hair loss and scalp pain, which may be related to the severity of their infection and treatment drugs.

Indian dermatologists recommend treating common hair loss with a balanced diet, stress reduction, mild shampoos, and sometimes minoxidil and supplements.

COVID-19 can cause hair loss, and treatments like PRP and stem cells might help.

Non-scarring alopecia in females affects emotional well-being and requires accurate diagnosis and personalized treatment.

Weight loss can cause temporary hair loss, especially in women and older adults.

Many people in Saudi Arabia experienced hair loss after COVID-19, especially women, those treated with antivirals, and those with a history of hair shedding.